Carbomer - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The carbomer market size was valued at USD 0.88 billion in 2025 and is estimated to grow from USD 0.93 billion in 2026 to reach USD 1.24 billion by 2031, at a CAGR of 5.89% during the forecast period (2026-2031). This report is segmented by Type (Carbomer 940, Carbomer 980, Carbomer 934, and More), Form (Powder, Liquid Dispersion, and Other Forms), Application (Personal Care and Cosmetics, Pharmaceuticals, Food and Beverage, Household and Institutional Care, and More), and Geography (Asia-Pacific, North America, Europe, South America, and Middle East and Africa). The Market Forecasts are Provided in Terms of Value (USD).

Global Carbomer Market Trends and Insights

Premium Personal Care and Cosmetic Formulation Demand

Brands are moving from standard carbomer 940 toward electrolyte-tolerant and high-clarity variants for products containing sodium hyaluronate, vitamin C derivatives, and mineral-rich botanical extracts. Ashland reported USD 155 million in Personal Care segment sales during the third quarter of fiscal year 2026, with 5% year-over-year growth and high-single-digit skin care growth. Standard carbomers can become unstable in high-electrolyte systems, so brands often upgrade their grade rather than replace the polymer, preserving product appearance and performance without changing a familiar product format. This response can increase carbomer revenue per unit even when finished-product volumes remain unchanged, because specialty grades require more exact specifications. The pattern is particularly visible in premium Asia-Pacific skin care, where Korean and Japanese formulation practices influence manufacturing in China.

Growth in Topical and Ophthalmic Pharmaceutical Formulations

Pharmaceutical-grade carbomers retain an important role in the carbomer market for topical and ophthalmic products because bioadhesion and mucoadhesion directly affect formulation performance. The U.S. Food and Drug Administration guidance on topical ophthalmic drug products sets performance expectations for polymer-based gels, suspensions, and semi-solid formulations. Lubrizol reported in April 2026 that the alternative pharmaceutical-grade carbomers it tested contained 1,2-dichloroethane at 3,000 to 30,000 parts per million, above the United States Pharmacopeia's 5 parts per million limits. This quality gap makes source changes difficult for regulated drug products and limits purely price-based substitution, since a replacement requires material review and additional supporting documentation. The U.S. Food and Drug Administration has also addressed reformulation of drug products containing benzene-manufactured carbomers, narrowing the pool of suitable suppliers. A 2025 journal study reported 100% drug release over 8 hours from a Carbopol 940 ophthalmic gel, demonstrating the polymer’s potential in sustained-release ocular delivery.

Tightening Polymer, Microplastics, and Chemical-Compliance Requirements

European Union restrictions on synthetic polymer microparticles place new compliance obligations on personal care products that use carbomers. European Commission Regulation (EU) 2023/2055 established a phased restriction framework, and the June 2026 amendment clarified the conditions for the solid-matrix derogation. Rinse-off cosmetics face an October 2027 deadline, leave-on products have an October 2029 deadline, and color cosmetics have an October 2035 deadline, requiring separate planning across product categories. These dates require reformulation, stability assessment, safety work, and sensory testing across multiple product lines, creating a workload that can be difficult for brands with extensive product portfolios. SEPPIC states that more than 1,500 new skin care products containing carbomer enter the European Union market each year. Multinational brands may apply stricter European requirements to products sold elsewhere, extending the compliance effect beyond the European Union.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of High-Performance and Electrolyte-Tolerant Grades
• Asia-Pacific Manufacturing and Formulation Capacity Expansion
• Formulation Sensitivity to pH, Electrolytes, and Neutralization Conditions

Segment Analysis

Carbomer 940 held 38.23% of the market revenue in 2025. Its established use in transparent gels, hand sanitizers, facial serums, and ophthalmic gel vehicles supports this position across several high-volume product formats. The grade provides viscosity, optical clarity, and scalable production economics that suit high-volume personal care manufacturing. Carbomer 934 has a specialized role in pharmaceutical tablet binding and controlled-release oral dosage forms. Carbomer 941 offers lower viscosity and better flow for pump dispensers, oral care, hair care, and topical pharmaceutical gels. Other types include hydrophobically modified acrylate copolymers and electrolyte-tolerant grades that offer more stable performance in complex active-ingredient systems.

Carbomer 980 is projected to advance at a 6.81% CAGR through 2031. Its benzene-free synthesis profile supports pharmaceutical residual-solvent requirements and cosmetics brands’ clean-chemistry programs. Lubrizol’s April 2026 tests highlighted pharmaceutical-grade purity and Class 1 solvent control as decisive criteria for regulated drug development. Producers in China are upgrading from Carbomer 940 synthesis toward Carbomer 980 to serve buyers requiring clean-solvent certificates. U.S. Food and Drug Administration guidance on benzene-manufactured carbomers also supports migration to alternative excipient grades. The Carbomer industry, therefore, sees rising demand for grades supported by stronger documentation and compliant synthesis routes.

Complete Report Scope:

• By Type
  • Carbomer 940
  • Carbomer 980
  • Carbomer 934
  • Carbomer 941
  • Other Types
• By Form
  • Powder
  • Liquid Dispersion
  • Other Forms
• By Application
  • Personal Care and Cosmetics
  • Pharmaceuticals
  • Food and Beverage
  • Household and Institutional Care
  • Other Applications
• By Geography
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

Asia-Pacific held 40.51% of the market revenue in 2025 and is projected to advance at a 7.40% CAGR through 2031. China serves as a low-cost production base and an expanding end-user location for personal care and pharmaceutical formulations. India is also driving demand as pharmaceutical manufacturing capacity supports demand for topical dosage ingredients. Sumitomo Seika Chemicals Co., Ltd. supplies the AQUPEC series to Japanese pharmaceutical and cosmetics manufacturers seeking benzene-free and halogen-free synthesis documentation. The carbomer market in the region is also shaped by closer links between local polymer production, formulation work, and end-user manufacturing, which support shorter supply routes and faster response to customer specifications.

North America remained an important regional area for pharmaceutical and personal care applications. Premium grades can command higher prices in this setting because customers prioritize application performance and quality documentation. Lubrizol identifies its Calvert City, Kentucky, location as a dedicated production site for Carbopol polymers are used in personal care, pharmaceuticals, and home care. BASF opened a Good Manufacturing Practice Solution Center in Wyandotte, Michigan, in June 2025 to support pharmaceutical excipient innovation. BASF announced a global price adjustment for pharmaceutical excipients and selected active pharmaceutical ingredients in March 2026, reflecting input-cost pressure across the supply chain. Ashland recorded USD 180 million in Life Sciences sales during the third quarter of fiscal year 2026, an 11% increase from the prior-year period. The carbomer market in North America, therefore, remains closely tied to pharmaceutical procurement standards, dependable supply, and formulation support for higher-value products.

Europe faces the most demanding reformulation conditions within the carbomer market. The June 2026 European Union amendment clarified synthetic polymer microparticle requirements for cosmetic applications. Germany, the United Kingdom, and France support demand through established generic and specialty pharmaceutical production. South America and the Middle East and Africa remain smaller regional markets. Brazil supports South American demand through generic pharmaceutical manufacturing. Saudi Arabia and the United Arab Emirates contribute to the demand for gel-based personal care and pharmaceutical products. The carbomer market in these smaller regions depends on the pace of local pharmaceutical production and on consumer demand for gel-based personal care formats.

List of Companies Covered in this Report:

• AcryliCon Polymers GmbH
• Anhui Newman Fine Chemicals Co., Ltd.
• Ashland
• BASF
• Chemtex Speciality Limited
• Corel Pharma Chem
• Dow
• Evonik Industries AG
• Guangzhou DX Chemical Co., Ltd.
• Guangzhou Tinci Materials Technology Co., Ltd.
• Lubrizol
• Maruti Chemicals
• SNF Group
• SUMITOMO SEIKA CHEMICALS CO., LTD.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support